These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30107664)

  • 1. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
    Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
    Ubukata Y; Ogata K; Sohda M; Yokobori T; Shimoda Y; Handa T; Nakazawa N; Kimura A; Kogure N; Sano A; Sakai M; Ogawa H; Kuwano H; Shirabe K; Oyama T; Saeki H
    Oncology; 2021; 99(1):15-22. PubMed ID: 33113541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
    Qing Y; Li Q; Ren T; Xia W; Peng Y; Liu GL; Luo H; Yang YX; Dai XY; Zhou SF; Wang D
    Drug Des Devel Ther; 2015; 9():901-9. PubMed ID: 25733810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
    Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
    Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
    Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Jan; 38(1):107-112. PubMed ID: 29277762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
    Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
    Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
    Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
    Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
    Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
    Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
    Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
    DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
    Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
    Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand (PD-L1) Expression in┬áStage II and III Lung Adenocarcinomas and Nodal┬áMetastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.